News | November 27, 2021
Fifty-five manufacturers selected for Pharma PLI sector
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
